These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 8117405)
21. Reversible sensorineural hearing loss with intravenous erythromycin lactobionate. Karmody CS; Weinstein L Ann Otol Rhinol Laryngol; 1977; 86(1 Pt 1):9-11. PubMed ID: 835977 [TBL] [Abstract][Full Text] [Related]
22. Multiple drug interactions with cyclosporine in a heart transplant patient. Zylber-Katz E Ann Pharmacother; 1995 Feb; 29(2):127-31. PubMed ID: 7756709 [TBL] [Abstract][Full Text] [Related]
23. Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin--ergotamine drug interaction. Bird PA; Sturgess AD Aust N Z J Med; 2000 Oct; 30(5):635-6. PubMed ID: 11108077 [No Abstract] [Full Text] [Related]
24. Dirithromycin: a new macrolide. Wintermeyer SM; Abdel-Rahman SM; Nahata MC Ann Pharmacother; 1996 Oct; 30(10):1141-9. PubMed ID: 8893122 [TBL] [Abstract][Full Text] [Related]
25. Effects of intravenous erythromycin lactobionate in respiratory infections. Di Sciacca A; Durante F; Cucchiara G; Ingrassia A; Mira G; Mannone F; Di Piazza RM; Frontini A; Barbagallo Sangiorgi G J Int Med Res; 1987; 15(4):245-50. PubMed ID: 3653502 [TBL] [Abstract][Full Text] [Related]
26. Ototoxic liability of erythromycin and analogues. Brummett RE Otolaryngol Clin North Am; 1993 Oct; 26(5):811-9. PubMed ID: 8233490 [TBL] [Abstract][Full Text] [Related]
31. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Principi N; Esposito S Drug Saf; 1999 Jan; 20(1):25-41. PubMed ID: 9935275 [TBL] [Abstract][Full Text] [Related]
32. Comparison of two oral forms of erythromycin in the treatment of acute respiratory tract infections. A multicentre general practice study. Macklin J; Barden R; Coles S J Int Med Res; 1989; 17(3):287-94. PubMed ID: 2670633 [TBL] [Abstract][Full Text] [Related]
33. Interaction between cyclosporin and erythromycin in a kidney transplant patient. Kessler M; Louis J; Renoult E; Vigneron B; Netter P Eur J Clin Pharmacol; 1986; 30(5):633-4. PubMed ID: 3530783 [No Abstract] [Full Text] [Related]
34. Treatment of respiratory tract infections with erythromycin acistrate and two formulations of erythromycin base. Wuolijoki E; Flygare U; Hildén M; Hurme J; Järvinen H; Leskinen J; Pynnönen S; Riikonen A; Salomaa V; Seuri M J Antimicrob Chemother; 1988 Jun; 21 Suppl D():107-12. PubMed ID: 3391872 [TBL] [Abstract][Full Text] [Related]
35. [Experiences with erythromycin in infant infections, especially respiratory tract infections]. Sander C Klin Padiatr; 1972 Jan; 184(1):55-8. PubMed ID: 4402000 [No Abstract] [Full Text] [Related]
36. Another look at erythromycin. Straughan JL S Afr Med J; 1978 Apr; 53(14):527-30. PubMed ID: 354037 [TBL] [Abstract][Full Text] [Related]
37. Erythromycin estolate in general practice. A comparative trial of two dosage forms. Grainger GJ Practitioner; 1969 Jul; 202(213):84-6. PubMed ID: 4895696 [No Abstract] [Full Text] [Related]
39. Hepatotoxic reaction to erythromycin ethylsuccinate. Patel J; Schneider R South Med J; 1984 Oct; 77(10):1343-4. PubMed ID: 6333077 [No Abstract] [Full Text] [Related]
40. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. Cakaloglu Y; Tredger JM; Devlin J; Williams R Hepatology; 1994 Aug; 20(2):309-16. PubMed ID: 7519161 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]